Ballentine Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.61M | Sell |
5,245
-2
| -0% | -$886 | 0.03% | 182 |
|
|
2026
Q1 | $2.34M | Sell |
5,247
-43
| -0.8% | -$20.1K | 0.03% | 180 |
|
|
2025
Q4 | $2.4M | Buy |
5,290
+200
| +4% | +$86.2K | 0.03% | 169 |
|
|
2025
Q3 | $1.99M | Sell |
5,090
-338
| -6% | -$141K | 0.03% | 196 |
|
|
2025
Q2 | $2.42M | Sell |
5,428
-409
| -7% | -$188K | 0.04% | 168 |
|
|
2025
Q1 | $2.83M | Buy |
5,837
+247
| +4% | +$115K | 0.05% | 135 |
|
|
2024
Q4 | $2.25M | Buy |
5,590
+119
| +2% | +$55.2K | 0.04% | 157 |
|
|
2024
Q3 | $2.54M | Buy |
5,471
+123
| +2% | +$59.1K | 0.04% | 143 |
|
|
2024
Q2 | $2.51M | Buy |
5,348
+470
| +10% | +$204K | 0.05% | 131 |
|
|
2024
Q1 | $2.04M | Buy |
4,878
+309
| +7% | +$131K | 0.04% | 151 |
|
|
2023
Q4 | $1.86M | Buy |
4,569
+201
| +5% | +$74.3K | 0.04% | 149 |
|
|
2023
Q3 | $1.52M | Buy |
4,368
+892
| +26% | +$312K | 0.04% | 149 |
|
|
2023
Q2 | $1.22M | Buy |
3,476
+131
| +4% | +$44.1K | 0.03% | 179 |
|
|
2023
Q1 | $1.05M | Buy |
3,345
+893
| +36% | +$268K | 0.03% | 189 |
|
|
2022
Q4 | $708K | Buy |
2,452
+436
| +22% | +$133K | 0.02% | 226 |
|
|
2022
Q3 | $584K | Buy |
2,016
+504
| +33% | +$145K | 0.02% | 224 |
|
|
2022
Q2 | $426K | Buy |
1,512
+131
| +9% | +$35.1K | 0.02% | 261 |
|
|
2022
Q1 | $360K | Sell |
1,381
-279
| -17% | -$66.2K | 0.01% | 314 |
|
|
2021
Q4 | $364K | Buy |
+1,660
| New | +$323K | 0.01% | 333 |
|
|
2021
Q3 | – | Sell |
-1,023
| Closed | -$206K | – | 438 |
|
|
2021
Q2 | $206K | Sell |
1,023
-84
| -8% | -$17.6K | 0.01% | 398 |
|
|
2021
Q1 | $238K | Sell |
1,107
-128
| -10% | -$28.1K | 0.01% | 343 |
|
|
2020
Q4 | $291K | Sell |
1,235
-227
| -16% | -$52.1K | 0.01% | 291 |
|
|
2020
Q3 | $398K | Buy |
1,462
+16
| +1% | +$4.41K | 0.02% | 232 |
|
|
2020
Q2 | $420K | Sell |
1,446
-49
| -3% | -$13.3K | 0.02% | 226 |
|
|
2020
Q1 | $356K | Buy |
1,495
+84
| +6% | +$19.3K | 0.02% | 227 |
|
|
2019
Q4 | $309K | Buy |
1,411
+58
| +4% | +$11.7K | 0.01% | 296 |
|
|
2019
Q3 | $230K | Sell |
1,353
-8
| -0.6% | -$1.42K | 0.01% | 347 |
|
|
2019
Q2 | $250K | Buy |
+1,361
| New | +$238K | 0.01% | 321 |
|
|
2017
Q4 | – | Sell |
-1,825
| Closed | -$277K | – | 426 |
|
|
2017
Q3 | $277K | Sell |
1,825
-3
| -0.2% | -$452 | 0.02% | 287 |
|
|
2017
Q2 | $295K | Buy |
+1,828
| New | +$220K | 0.02% | 279 |
|
Other funds holding VRTX
Ballentine Partners's VRTX Position: Q2 2026 in Review
Ballentine Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 0.04% in Q2 2026, selling an estimated $886 and leaving 5,245 shares worth $2.61M. The position accounts for 0.03% of the portfolio, ranked #182.
Ballentine Partners first reported a position in VRTX in Q2 2017 and has held it in 30 quarters since. The position peaked at $2.83M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Ballentine Partners held 5,245 shares of Vertex Pharmaceuticals worth $2.61M as of Q2 2026.
- Ballentine Partners sold 2 Vertex Pharmaceuticals shares in Q2 2026, an estimated $886.
- Vertex Pharmaceuticals made up 0.03% of Ballentine Partners's portfolio in Q2 2026, its #182 holding.
- Ballentine Partners first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
- Ballentine Partners's Vertex Pharmaceuticals position peaked at $2.83M in Q1 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.